Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE0005203947
Thu, 12.12.2024
BRAIN Biotech AG
BRAIN Biotech AG Sharpens Focus on Profitable Growth
Combination of BioProducts segment and BioScience Zwingenberg to form the growth segment BRAINBiocatalysts
Five-year targets in the BRAINBiocatalysts segment: revenues of EUR 100 million, 15 % adjusted EBITDA margin and high R&D ratio
Significant improvement in the liquidity and earnings s [ … ]
Thu, 31.10.2024
BRAIN Biotech AG
BRAIN Biotech AG and Akribion Therapeutics GmbH sign exclusive pharma licensing agreement for G-dase E® CRISPR-Cas technology
Akribion Therapeutics GmbH financed by strong Venture Capital Consortium with pharma expertise
BRAIN can receive up to EUR 92.3 million R&D and commercial milestone fees plus additional royalties in exchange for granti [ … ]
Thu, 03.10.2024
BRAIN Biotech AG
Prof. Dr. Wiltrud Treffenfeldt leaves Supervisory Board of BRAIN Biotech AG for personal reasons
Zwingenberg, Germany, October 03, 2024 – Professor Dr. Wiltrud Treffenfeldt has informed the Chairman and the other members of the Supervisory Board of the BRAIN Biotech AG that she wishes to resign from her position as an ordinary member of the Superv [ … ]
Fri, 20.09.2024
BRAIN Biotech AG
BRAIN Biotech AG concludes major pharma compound transaction valued up to EUR 128.88 million from its BioIncubator
Total transaction value up to EUR 128.88 million significantly exceeding current market capitalization of BRAIN Biotech
Immediate upfront payment of EUR 18.41 million
Royalty monetization of an investigational compound, deucrictiban [ … ]
Fri, 20.09.2024
BRAIN Biotech AG
BRAIN Biotech AG concludes major pharma compound transaction valued up to EUR 128.88 million from its BioIncubator
Total transaction value up to EUR 128.88 million significantly exceeding current market capitalization of BRAIN Biotech
Immediate upfront payment of EUR 18.41 million
Royalty monetization of an investigational compound, deucrictiban [ … ]
Thu, 29.08.2024
BRAIN Biotech AG
BRAIN Biotech AG presents strong cash position with its 9M reporting and is forecasting good sequential growth in the final quarter of the business year
Cash on-hand at € 13 million
Significantly improved operating cash-flow in the 9M
Forecasting a sequentially strong BioProducts quarter in Q4 FY 23/24
August 29, 2024, Zwingenberg/Germany – BRAI [ … ]
Wed, 29.05.2024
BRAIN Biotech AG
BRAIN Biotech AG announces the appointment of Erik de Vries as Senior Business Development Director Enzymes
Zwingenberg and Greifswald, May 29, 2024 – BRAIN Biotech AG and Enzymicals AG are pleased to announce that Dr. Erik de Vries will join BRAIN Biotech as Senior Business Development Director Enzymes as of June 1st, 2024. De Vries will continue [ … ]
Tue, 28.05.2024
BRAIN Biotech AG
BRAIN Biotech AG receives major milestone payment and stays on-track to achieve year end targets
Major milestone payment from pharma-project of € 1.5 million received
BioProducts business growth accelerated in Q2, further acceleration expected throughout H2
On-track to meet fiscal year end targets
Significantly strengthened cash position
Zwing [ … ]
Tue, 28.05.2024
BRAIN Biotech AG
BRAIN Biotech AG receives major milestone payment and stays on-track to achieve year end targets
Major milestone payment from pharma-project of € 1.5 million received
BioProducts business growth accelerated in Q2, further acceleration expected throughout H2
On-track to meet fiscal year end targets
Significantly strengthened cash position
Zwing [ … ]
Tue, 16.04.2024
BRAIN Biotech AG
BRAIN Biotech AG takes next step to optimize group structure
BRAIN Biotech Group will merge AnalytiCon Discovery GmbH into BRAIN Biotech AG in order to further optimize and simplify the Group structure.
Zwingenberg, Germany, 16 April 2024 – The Management Board of BRAIN Biotech AG, with the approval of the Supervisory Board, has resolved to merge [ … ]